Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Non-Current Deffered Revenue (2016 - 2025)

Macrogenics (MGNX) has disclosed Non-Current Deffered Revenue for 14 consecutive years, with $55.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue changed 0.0% to $55.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $55.5 million, a 0.0% change, with the full-year FY2025 number at $55.5 million, changed 0.0% from a year prior.
  • Non-Current Deffered Revenue was $55.5 million for Q4 2025 at Macrogenics, down from $55.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $64.3 million in Q3 2023 to a low of $7.3 million in Q1 2021.
  • A 5-year average of $49.8 million and a median of $55.9 million in 2025 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 690.63% in 2022, then decreased 13.63% in 2024.
  • Macrogenics' Non-Current Deffered Revenue stood at $9.6 million in 2021, then skyrocketed by 521.2% to $59.5 million in 2022, then dropped by 0.4% to $59.2 million in 2023, then dropped by 6.31% to $55.5 million in 2024, then changed by 0.0% to $55.5 million in 2025.
  • Per Business Quant, the three most recent readings for MGNX's Non-Current Deffered Revenue are $55.5 million (Q4 2025), $55.8 million (Q3 2025), and $55.7 million (Q2 2025).